Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

Zielinski Christoph, Láng István, Beslija Semir, Kahán Zsuzsanna, Inbar Moshe J., Stemmer Salomon M., Anghel Rodica, Vrbanec Damir, Messinger Diethelm, Brodowicz Thomas
2016

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

Pascual Javier, Gil-Gil Miguel, Proszek Paula, Zielinski Christoph, Reay Alistair, Ruiz-Borrego Manuel, Cutts Rosalind, Ciruelos Gil Eva M, Feber Andrew, Muñoz-Mateu Montserrat, Swift Claire, Bermejo Begoña, Herranz Jesus, Kahán Zsuzsanna, Csöszi Tibor
2023

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cance...

Vrdoljak Eduard, Marschner N., Zielinski Christoph Carl, Gligorov Joseph, Cortes Javier, Puglisi Fabio, Aapro Matti S., Fallowfield Lesley J., Fontana Andrea, Inbar Moshe Josef, Kahán Zsuzsanna, Welt Anja, Lévy Christelle, Brain Étienne G.C, Pivot Xavier B.
2016

Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe An initiative of the Central European Cooperative Oncology Group (CECOG)

Thallinger Christiane, Berzinec Peter, Bicakcic Emina, Dan Adelina, Fábián Gabriella, Gales Laurentia Nicoletta, Kuhar Cvetka Grasic, Janzic Urska, Kahán Zsuzsanna, Mencinger Marina, Penthedourakis George, Sgouros Joseph, Simetic Luka, Sirbu Daniela, Vosmik Milan, Wrona Anna, Zielinski Christoph
2022

Selecting first-line bevacizumab-containing therapy for advanced breast cancer TURANDOT risk factor analyses /

Brodowicz Thomas, Láng István, Kahán Zsuzsanna, Greil R., Beslija Semir, Stemmer Salomon M., Kaufman B., Petruzelka L., Eniu A., Anghel Rodica, Koynov K., Vrbanec Damir, Pieńkowski Tadeusz, Melichar B., Spanik S., Ahlers S., Messinger Diethelm, Inbar Moshe J., Zielinski Christoph
2014